论文部分内容阅读
目的探讨短期应用辛伐他汀对急性冠状动脉综合征(ACS)患者早期血浆C-反应蛋白(CRP)和基质金属蛋白酶-9(MMP-9)的影响。方法经临床诊断ACS46例,随机分为治疗组和对照组,各23例。对照组给予ACS的一般治疗,不予任何降脂药;治疗组除给予ACS的一般治疗外,加服辛伐他汀40mg/d,共3d。用免疫比浊法和酶联免疫吸附法(ELISA)分别检测2组患者血清CRP和MMP-9。结果2组患者治疗前、后血脂TC、TG、HDL-C、LDL-C的比较差异无统计学意义。2组治疗前和对照组治疗前后的血浆CRP、MMP-9比较差异无统计学意义;治疗组CRP和MMP-9治疗后较治疗前分别下降39.82%和32.39%,均差异有统计学意义(P<0.05)。结论应用辛伐他汀短期治疗ACS患者能够使CRP和MMP-9显著下降,说明他汀类早期应用有抗炎、稳定斑块及防止斑块破裂的作用。
Objective To investigate the effects of short-term simvastatin on plasma C-reactive protein (CRP) and matrix metalloproteinase-9 (MMP-9) in patients with acute coronary syndrome (ACS). Methods The clinical diagnosis of ACS46 cases were randomly divided into treatment group and control group, 23 cases each. The control group was given general treatment of ACS without any lipid-lowering drug. In addition to the general treatment of ACS, the treatment group was given simvastatin 40 mg / d for 3 days. Serum CRP and MMP-9 levels were measured by immunoturbidimetry and enzyme-linked immunosorbent assay (ELISA). Results There was no significant difference in the levels of TC, TG, HDL-C and LDL-C between the two groups before and after treatment. There was no significant difference in plasma CRP and MMP-9 levels between the two groups before and after treatment. The CRP and MMP-9 levels in the treatment group decreased by 39.82% and 32.39% compared with before treatment, respectively, with significant difference (P < P <0.05). Conclusions Short-term treatment with simvastatin can significantly decrease CRP and MMP-9, suggesting that anti-inflammatory, stable plaque and prevention of plaque rupture may be the early use of statins.